Current Report Filing (8-k)
June 03 2019 - 1:17PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event
reported): June 3, 2019 (May 28, 2019)
CALMARE THERAPEUTICS INCORPORATED
(Exact name of registrant as specified
in its charter)
|
Delaware
|
|
001-08696
|
|
36-2664428
|
|
(State or other jurisdiction
|
|
(Commission File Number)
|
|
(IRS Employer
|
|
of Incorporation)
|
|
|
|
Identification Number)
|
|
|
|
1375 Kings Highway East
|
|
|
|
|
|
Fairfield, CT 06824
|
|
|
|
|
|
(Address of principal executive offices)
|
|
|
|
|
|
203-368-6044
|
|
|
|
|
|
(Registrant’s Telephone Number)
|
|
|
N/A
(Former name or former address, if changed
since last report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the
Act:
None
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
|
Indicate by check mark whether the
registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or
Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
As set forth in the Registrant’s
Form 10-K for the fiscal year ended December 31, 2016 (the “2016 10-K”), on August 22, 2014, GEOMC filed a complaint
against the Registrant in the United States District Court for the District of Connecticut. The allegations included in that complaint,
as amended, are described in the 2016 10-K. On September 29, 2017, the District Court entered a final judgment that awarded GEOMC,
among other relief, monetary damages of $4,673,406, in addition to pre-judgment interest of $5,678,764, with both amounts totaling
$10,352,170. Calmare appealed the judgment to the United States Court of Appeals for the Second Circuit.
On March 12, 2019, the United States
Court of Appeals for the Second Circuit vacated the District Court’s judgment and remanded the case to the District Court
for further proceedings.
On May 28, 2019, the United States Court
of Appeals for the Second Circuit denied a petition for panel rehearing filed by GEOMC.
The information in this Item 8.01 of
this Form 8-K is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange
Act of 1934, or otherwise subject to the liabilities of that section. The information in this Item 8.01 of this Form 8-K also shall
not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange
Act of 1934, except to the extent that the Company specifically incorporates it by reference.
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
June 3, 2019
By:
/s/
Conrad Mir
Conrad Mir
Chief
Executive Officer
Calmare Therapeutics (CE) (USOTC:CTTC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Calmare Therapeutics (CE) (USOTC:CTTC)
Historical Stock Chart
From Apr 2023 to Apr 2024
